https://www.miragenews.com/md-anderson-secures-inducible-switch-t...

https://www.miragenews.com/md-anderson-secures-inducible-switch-tech-for-1179490/

"As a result of this acquisition, MD Anderson may incorporate these platforms into its own cell therapy programs"

It looks like these platforms enhance safety and efficacy.

"MD Anderson plans to focus on using the CaspaCIDe technology as a safety feature of cell therapies in development. The safety switch incorporates an inducible enzyme known as caspase-9, which initiates the first step of the apoptosis programmed cell death pathway. The switch can be triggered by rimiducid, leading to rapid elimination of cells containing the CaspaCIDe switch"

The asset acquisition also includes the transfer of certain intellectual property related to Bellicum's GoCAR-T™ and GoCAR-NK™ technologies. Using the rimiducid-based switch system, GoCAR cell therapies feature an inducible MyD88/CD40 (iMC) activation switch designed to enhance proliferation and functional persistence of adoptive cell therapies by resisting exhaustion and by driving production of immunomodulatory cytokines to overcome inhibitory signals from the tumor microenvironment. GoCAR cell therapies may be particularly well-suited for use in solid tumors given their immune suppressive tumor microenvironment.

https://www.bellicum.com/gocar-technology/
https://www.bellicum.com/caspacide-safety-switch/

I just pumped into this on the Clinical trials page at MD Anderson. We're in safe hands.

In FY23, the FDA approved 43 new cancer drugs for public, clinical use.MD Andersoncontributed to the development of 25 of those — nearly 60%.